• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care
Prostate Cancer : Episode 4

Episode 4 - Treatment Guidelines and Economic Considerations

Video

During this segment, Raoul S. Concepcion, MD, explains how the rapid development of agents for castration-resistant prostate cancer (CRPC) has led to an expanding number of clinical guidelines, developed by multiple organizations, for clinicians’ use during important treatment-decisions.

However, he explains that the treatment options recommended in these guidelines are expensive, creating a challenge to both clinicians and payers.

To clarify misconceptions about medical policy and coverage for patients with CRPC, Michael Kolodziej, MD, discusses the variables that payers consider when making decisions about coverage for these expensive treatment options.


Related Videos
Amit Singal, MD, UT Southwestern Medical Center
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Rashon Lane, PhD, MA
Dr Sophia Humphreys
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Ryan Stice, PharmD
Leslie Fish, PharmD.
Ronesh Sinha, MD
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.